Skip to main content

Table 1 Clinical characteristics of 5–2-1-positive and 5–2-1-negative patients

From: Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

  All patients (n = 4714)a 5–2-1 positive (n = 1546)a 5–2-1 negative (n = 3168)a P-value
Patient age
 Mean (SD) 69.3 (10.6) 71.7 (10.4) 68.2 (10.5) < 0.0001
 ≥65 years, n (%) 3309 (70.2) 1231 (79.6) 2078 (65.6) < 0.0001
Gender, n (%)
 Male 2866 (60.8) 964 (62.4) 1902 (60.0) 0.1274
Charlson Comorbidity Index, mean (SD) 0.4 (1.0) 0.6 (1.2) 0.3 (0.9) < 0.0001
Charlson Comorbidity Index, n (%)
 None (score 0) 3765 (79.9) 1108 (71.7) 2657 (83.9) < 0.0001
 Mild (score 1–2) 787 (16.7) 357 (23.1) 430 (13.6)  
 Moderate (score 3–4) 120 (2.5) 62 (4.0) 58 (1.8)  
 Severe (score 5+) 42 (0.9) 19 (1.2) 23 (0.7)  
Time since PD diagnosis (years), mean (SD) 4.3 (4.4) (n = 3712) 7.2 (5.1) (n = 1162) 3.0 (3.2) (n = 2550) < 0.0001
Physician judgment of PD stage, n (%)
 Non-advanced 4012 (85.1) 994 (64.3) 3018 (95.3) < 0.0001
 Advanced 702 (14.9) 552 (35.7) 150 (4.7)  
Hoehn and Yahr stage, n (%)
 1 1593 (33.8) 1579 (39.4) 14 (2.0) < 0.0001
 2 1545 (32.8) 1492 (37.2) 53 (7.5)  
 3 932 (19.8) 778 (19.4) 154 (21.9)  
 4 457 (9.7) 147 (3.7) 310 (44.2)  
 5 187 (4.0) 16 (0.4) 171 (24.4)  
  1. PD Parkinson’s disease, SD Standard deviation
  2. aPatient number unless otherwise stated